Surufatinib as Neoadjuvant Treatment for Locally Advanced or Metastatic Differentiated Thyroid Cancer

This study tests surufatinib — a targeted drug that blocks blood vessel growth and certain immune pathways — as a treatment before or alongside other therapies for people with locally advanced or widespread differentiated thyroid cancer that is difficult to treat surgically. **You may be eligible if...** - You have confirmed differentiated thyroid cancer (papillary, follicular, or poorly differentiated types) - Your cancer is locally advanced (spreading into nearby structures) or has spread to distant organs (metastatic) **You may NOT be eligible if...** - Your thyroid cancer is a different type (e.g., medullary or anaplastic) - Your cancer has not spread locally or to distant sites - You have health conditions that prevent you from tolerating the study drug Talk to your doctor to see if this trial is right for you.